DALLAS, TX — Gradalis Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control. GRAD1405 is a single agent that has demonstrated the ability to consistently reduce three KRAS mutant proteins: KRAS G12C, G12D and G12V, which are responsible for the rapid...
treatment News
Bethesda, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of €1.2 million to a consortium led...
John Steinbeck’s epic novel, Grapes of Wrath, captures the pilgrimage of the Joad family from Oklahoma to California and their individual and collective struggles along the journey. Steinbeck could easily write a similar saga titled Grapes of Health for a molecule from grapes that is being targeted for treating rare...
John Steinbeck’s epic novel, Grapes of Wrath, captures the pilgrimage of the Joad family from Oklahoma to California and their individual and collective struggles along the journey. Steinbeck could easily write a similar saga titled Grapes of Health for a molecule from grapes that is being targeted for treating rare...
SOUTH SAN FRANCISCO, Calif. – Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational...
ROCHESTER, Minn. — Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea. The trial determined that patients with chronic lymphocytic leukemia (CLL) can tolerate the chemical fairly well when high doses are administered in capsule...
STAFFORD, Texas — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company’s application...
NEW YORK, NY – GRIN Therapeutics Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced initiation of the Astroscape study, the Company’s global open-label clinical trial of radiprodil, an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype 2B (NR2B or...
Brussels, Belgium – During the surgery Wednesday April 17, the Da Vinci Xi surgical system was combined with MMI’s Symani surgical system. In collaboration with abdominal surgeon Dr Martijn Schoneveld, the plastic and reconstructive surgery team performed a fully robotic lymph node transplant, overseen by Professor Moustapha Hamdi, Head of...
San Francisco, Calif. – A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start. Researchers hope the trial, which will be led by UC...